Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk B Mendel

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 30, 2002
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in miceA Douglas Laird, Jmes G Christensen, Guangmin Li, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 2013
Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patientsSarah Walter, Amos Baruch, Jin Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignanciesCheryl A London, Alison L Hannah, Regina Zadovoskaya, et al.
Cancer Research|November 13, 2003
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivoJames G Christensen, Randall Schreck, Jon Burrows, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in miceXiaohua Xin, Tinya J Abrams, Paul W Hollenbach, et al.
Molecular Cancer Therapeutics|August 8, 2006
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activityShem Patyna, A Douglas Laird, Dirk B Mendel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipDirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 30, 2002
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in miceA Douglas Laird, Jmes G Christensen, Guangmin Li, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 2013
Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patientsSarah Walter, Amos Baruch, Jin Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignanciesCheryl A London, Alison L Hannah, Regina Zadovoskaya, et al.
Cancer Research|November 13, 2003
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivoJames G Christensen, Randall Schreck, Jon Burrows, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in miceXiaohua Xin, Tinya J Abrams, Paul W Hollenbach, et al.
Molecular Cancer Therapeutics|August 8, 2006
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activityShem Patyna, A Douglas Laird, Dirk B Mendel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipDirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Pageof 2